• Read Next

|
Sign In
U.S. tariffs on drugs may be coming, but Amgen manufactures most of its products in the U.S. , keeping its costs under control. (Courtesy Amgen)

Amgen Is Getting Into the Obesity Drug Business. The Stock Could Become the Next Winner.

Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits significantly in the years ahead.

By Jacob Sonenshine

April 10, 2025, 1:00 am EDT

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Advertisement - Scroll to Continue

Read Next

Chevron’s Buyback Strategy at Center Stage as It Prepares to Report Earnings

Chevron’s Buyback Strategy at Center Stage as It Prepares to Report Earnings

Why the AI Trade May Not Save the Market From Trump’s Tariffs for Long

Why the AI Trade May Not Save the Market From Trump’s Tariffs for Long

McDonald’s Saw a Big Drop in Customer Traffic. The Stock May Not Be Recession-Proof After All.

McDonald’s Saw a Big Drop in Customer Traffic. The Stock May Not Be Recession-Proof After All.